J&J's Talvey-Darzalex Combo Outperforms Standard of Care in Myeloma, Submits for FDA/EMA Expansion
JNJ sits 61% above its 52-week low of $149.04.
Summary
Johnson & Johnson announced strong new clinical data for its Talvey and Darzalex Faspro combination therapy in earlier-line relapsed or refractory multiple myeloma. The data demonstrated the combination outperformed standard of care in progression-free survival (PFS) and overall survival (OS) at 24 months, alongside a consistent safety profile. The company has submitted a supplemental Biologics License Application (sBLA) to the FDA and a Type II Variation to the EMA based on these results. This development strengthens J&J's oncology portfolio and could significantly expand the market for these drugs, building on recent positive drug news for the company. The market will now await regulatory decisions from the FDA and EMA.
At the time of this announcement, JNJ was trading at $240.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $579.8B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.